<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01132235</url>
  </required_header>
  <id_info>
    <org_study_id>ENBRECAP2009</org_study_id>
    <nct_id>NCT01132235</nct_id>
  </id_info>
  <brief_title>An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use</brief_title>
  <acronym>ENBRECAP2009</acronym>
  <official_title>An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florida Academic Dermatology Centers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Florida Academic Dermatology Centers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of re-treatment with etanercept 50mg
      subcutaneous injections twice weekly for 12 weeks in subjects who have previously been
      treated etanercept and efficacy diminished.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients achieving a Physician's Global Assessment (PGA) score of minimal (1) or clear (0) at week 12.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Physician's Global Assessment (PGA) score of minimal (1) or clear (0) at week 12 will measure efficacy of retreatment with etanercept</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Psoriasis</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>etanercept</intervention_name>
    <description>50mgs subcutaneous injections twice a week for 12 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with psoriasis who have previously been treated with etanercept for a minimum
             of 6 months and discontinued treatment due to loss of efficacy. Every attempt will be
             made to obtain loss of efficacy history from the subject's medical chart;when
             etanercept was commenced and terminated and description of patient's psoriasis on
             termination and details of new treatment commenced. Subjects must have failed their
             latest psoriasis treatment after a period of three months. This will be measured as a
             PGA of ≥ 3.

          -  There is no specific requirement as to when prior treatment with etanercept occurred
             and no requirement as to what type of treatment(s) used between initial and subsequent
             treatments.

          -  Are ≥ 18 years of age

          -  PGA ≥ 3

          -  BSA minimum of 5%

        Tuberculosis inclusion criteria

          -  Have no history of latent or active TB prior to screening.

          -  Have no signs or symptoms suggestive of active TB upon medical history and/or physical
             examination.

          -  Have had no recent close contact with a person with active TB.

          -  Within 1 month prior to the first administration of study have a negative tuberculin
             skin test.

               -  The ability to give written informed consent and comply with study procedures.

        Exclusion Criteria:

          -  Current enrollment in any other investigational device or investigational drug
             trial(s), or receipt of any other investigational agent(s) within 28 days before
             baseline visit.

          -  Known hypersensitivity to Enbrel® (etanercept) or any of its components or known to
             have antibodies to etanercept.

          -  Latex sensitivity [NB: only applicable if they are using prefilled syringe or
             prefilled SureClick™ autoinjector presentations]

          -  Prior or concurrent use of cyclophosphamide therapy

          -  Concurrent sulfasalazine therapy.

          -  A positive HBV test or known history of any other immuno-suppressing disease.

          -  Any mycobacterial disease or high risk factors for tuberculosis (TB), such as family
             member with TB, positive purified protein derivative (PPD) or taking anti-tuberculosis
             medication.

          -  Active or chronic infection within 4 weeks before screening visit, or between the
             screening and baseline visits.

          -  History of listeriosis, histoplasmosis, chronic or active Hepatitis B infection and
             Hepatitis C, human immunodeficiency virus (HIV) infection, immunodeficiency syndrome,
             chronic recurring infections or active TB, or other opportunistic infections

          -  If etanercept was previously discontinued due to a serious adverse event

          -  Severe comorbidities (diabetes mellitus requiring insulin; CHF of any severity; or
             myocardial infarction, cerebrovascular accident or transient ischemic attack within 6
             months of screening visit; unstable angina pectoris; uncontrolled hypertension
             (sitting systolic BP &lt;80 mm Hg or &gt; 160 or diastolic BP &gt; 100 mm Hg); oxygen-dependent
             severe pulmonary disease; history of cancer within 5 years [other than resected
             cutaneous basal or squamous cell carcinoma of the skin or in situ cervical cancer])

          -  Systemic lupus erythematosus, history of multiple sclerosis, transverse myelitis,
             optic neuritis or seizure disorder.

          -  Use of a live vaccine 90 days prior to screening visit, or concurrent use of a live
             vaccine.

          -  Any condition or circumstances judged by the patient's physician [or the investigator
             or medically qualified study staff] to render this clinical trial detrimental or
             otherwise unsuitable for the patient's participation.

          -  Female subjects who are pregnant, nursing or planning pregnancy (both men and women)
             and not using acceptable methods of birth control during the trial (hormonal,
             barriers, abstinence).

          -  Women who are breast feeding

        History of non-compliance with other therapies.

          -  History of alcohol abuse within the last 12 months

          -  Concurrent use of anakinra

          -  Subjects who cannot discontinue any of the drugs below for 2 weeks prior to the
             baseline visit or during the study;

        A two week wash out period is appropriate as it would be unethical to expect subjects whose
        disease if flaring to remain untreated for a longer period of time. The first dose of
        etanercept will be administered two weeks after the last biologic dose.

          -  Immunosuppressants, antimalarials, or sulfasalazine.

          -  Other Ani-TNFs

          -  Cyclosporine

          -  Efalizumab

          -  Azathioprine

          -  Hydroxyurea

          -  Live vaccines

          -  Tacrolimus

          -  Oral retinoids (isotretinoin,acitretin,bexarotene)

          -  Ultra violet light therapies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Florida Academic Dermatology Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annika M Grant, RN.MBA</last_name>
      <phone>305-324-2110</phone>
      <phone_ext>210</phone_ext>
      <email>annikagrant@bellsouth.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2010</study_first_posted>
  <last_update_submitted>May 27, 2010</last_update_submitted>
  <last_update_submitted_qc>May 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Francisco A Kerdel, M.D.</name_title>
    <organization>Florida Academic Dermatology Centers</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

